Workshop on pediatric lymphomas: Current results and prospects

  • Sharon B. Murphy
  • Ian T. Magrath

Abstract

In the last 15 years we have witnessed a remarkable improvement in the survival rates of children and adolescents with Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) — an improvement that continues today. Just 20 years ago, only some 30–40% of children with localized NHL could be expected to achieve longterm survival, and vanishingly few with extensive disease survived. Currently 80–90% of all lymphomas, HD and NHL, are curable. This progress has been the result of many factors, not the least of these being the conduct of controlled clinical trials. The well-organized and disciplined trials conducted during the last decade by the German group for pediatric HD (see Table 1) are a model in this regard [1].

Keywords

Toxicity Lymphoma Lactate Leukemia Methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schellong G, Brämswig H, Schwarze EW, Wannemacher M. An approach to reduce treatment and invasive staging in childhood Hodgkin’s disease: the sequence of the German DAL Multicenter Studies. Bull Cancer 1988; 75: 41–52.PubMedGoogle Scholar
  2. 2.
    Bowman WP, Shuster J, Cook B, Behm F, Berard C, Murphy SB. Results of treatment for advanced stage (IV) diffuse small non-cleaved cell non-Hodgkins (NHL) lymphomas and B(SIg+) cell acute lymphoblastic leukemia (ALL): The Pediatric Oncology Group (POG) Experience, 1986–89. Abstract -40. Fourth International Conference on Malignant Lymphoma, Lugano, June, 1990.Google Scholar
  3. 3.
    Patte C, Perel Y, Leverger G, Rubie H, Otten J, Plantaz D, Munzer M, Boutard P, Benz-Lemoine E, Pautard B, Kalifa C. High survival rate of B-cell non Hodgkin’s lymphomas (B-NHL) with CNS involvement (CNS+) and B-ALL. Results of the LBM 86 protocol of the French Pediatric Oncology Society (SFOP). Abstract -39. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar
  4. 4.
    Reiter A, Sauter S, Miiller-Weihrich S, Kühl J, Gadner H, Riehm H. BFM therapy strategy and results in advanced childhood B-cell neoplasias (stage-IV B-NHL; BALL). Abstract -38. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar
  5. 5.
    Schellong G, Hörnig-Franz I, Brämswig J, Wannenmacher M. Hodgkin’s disease in children: treatment reduction by elimination of procarbazine from OPPA/COPP chemotherapy. Results of the German Cooperative Study DAL-HD-85. Abstract -32. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar
  6. 6.
    Bessa E, Oberlin O, Hartman O, Michon J, Bordigoni J, Hervé P, Demeocq, Plantaz D, Philip T, Michel G, Baruchel A, Leverger G. High-dose combination chemotherapy for childhood Hodgkin’s disease: The French Pediatric Oncology Society Experience. Abstract -33. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar
  7. 7.
    Magrath IT, Adde M, Sandlund J, Jain V. Ifosfamide (IF) in the treatment of high-grade, recurrent B cell lymphomas: experience of the Pediatric Branch, National Cancer Institute. Abstract -37. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar
  8. 8.
    Gad-El-Mawla N, Hamza MR, Abdel-Hadi S, Hussein MH, El-Tannir O, Magrath I. Prolonged disease free survival in pediatric non-Hodgkin’s lymphoma using ifosfamide containing combination chemotherapy. Abstract -36. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar
  9. 9.
    Philip T, Pinkerton R, Hartmann O, Patte C, Philip I, Biron P, Favrot M. The role of massive therapy with autologous bone marrow transplantation in Burkitt’s lymphoma. Clinics in Haematology 1986; 15: (1) 205–17.PubMedCrossRefGoogle Scholar
  10. 10.
    Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma: a morphologic and immunologic study of 19 cases. Am J Surg Pathol 1988; 12 (4): 264–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Bucsky P, Feller AC, Reiter A, Heitger A, Gadner H, Riehm H. Malignant histiocytosis and large cell anaplastic (Ki-1) lymphoma in children and adolescents - preliminary experiences of the BFM Study Group. Abstract -34. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar
  12. 12.
    Vecchi V, Pileri S, Burnelli R, Rosito P, Pession A, Rondelli R, Borghetti A, Paolucci G. Anaplastic large-cell lymphoma (Ki1+/CD30+) in childhood. Abstract -35. Fourth International Conference on Malignant Lymphoma, Lugano, June 1990.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • Sharon B. Murphy
    • 1
  • Ian T. Magrath
    • 2
  1. 1.Chief, Division of Hematology/Oncology, Children’s Memorial Hospital and Professor of PediatricsNorthwestern University School of MedicineUSA
  2. 2.Head, Lymphoma Biology Section, Pediatric Oncology Branch, Division of Cancer TreatmentNational Cancer InstituteUSA

Personalised recommendations